Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
. j4 b0 i `' U3 {2 K% H% y: f+ D* ~- ]' x% Z* J0 K
1 x, K4 w" X+ C1 t8 r
Sub-category:
1 E3 _2 q2 b3 i" a) kMolecular Targets
4 s( L7 J: _- p) l) W- a5 Q% b/ P$ }- h, U
2 ^0 b- U; @% C2 z
Category:7 l8 L# |% M5 P9 Q/ G
Tumor Biology
]1 f/ s# k/ K' @
2 H# x& R/ V" C' Q0 y! s7 E2 o+ o/ ~9 e5 W! U4 [3 y% C: W& P6 z
Meeting:
4 J& ~, n& t) ]6 ^+ K+ \2011 ASCO Annual Meeting 0 ]9 u6 x g0 j8 y8 K1 h4 p/ I
" ~/ _" j. h3 ]/ k
2 H3 l- I- ^8 I& _, @, G7 ^Session Type and Session Title:
: [2 L) [) r v0 k/ yPoster Discussion Session, Tumor Biology
9 X( n" j: i3 x5 ]' O# v' p' w9 g) M
& y% X% _& t, R; V! w" C9 wAbstract No:
3 _1 f7 G! t4 B6 f$ _10517 " O2 M- l1 ?+ K3 x* M. A
" m# }" x. |9 C! n9 z$ `1 Y5 N3 S
( z( M0 m3 r. B8 C+ k2 ?Citation:0 s: P& K) m6 A$ d
J Clin Oncol 29: 2011 (suppl; abstr 10517)
3 i3 a8 R& L! }2 ~( R2 C
; J/ w4 N3 R4 w2 m
3 w7 |# p! _" a0 B+ UAuthor(s):
9 W9 I# w. u8 R# q' [: }7 ^1 QJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
2 r/ v3 Z5 F: M, s N/ j6 Y0 Q1 j
y$ O/ b, {+ [$ B; `* [, ~7 V% G, k B/ w7 @
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
/ N3 z" x0 A: W V* N* ^7 c6 B0 d+ B( N, ~) q9 b$ d' \
Abstract Disclosures
* E/ Q% q* S0 E$ j) Z1 Z& B9 u, P6 D& q: c2 G/ k% l
Abstract:. M4 o0 h- G+ ~& [) [; ]# H
+ P7 Q8 u& w5 D+ R3 b
, D1 Q" g# Q/ G5 e5 A+ fBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
. C: Z) w3 r! t$ n6 R
7 [: P) |" w: w5 F; M
) A$ ~7 i/ Z8 C |
7 G# m& ?( \% ?3 u
显身卡
